India hardens trade stance against US, wants disputes to go to WTO
Source: Times of India 26 Feb 2014 NEW DELHI: The government is set to ask all its officials to stay away from any interaction with a delegation from the US International Trade Commission (USITC), a...
View ArticleMEDIA INVITE: Photo opportunity as health activists take to the streets
Source: Fix The Patent Laws 11 March 2014 MEDIA INVITE: PHOTO OPPORTUNITY FIX THE PATENT LAWS CAMPAIGN TUESDAY MARCH 11 – Department of Trade and Industry (DTI) offices, PRETORIA THURSDAY MARCH 13 –...
View ArticlePRESS RELEASE: INDIAN HEALTH MINISTRY URGED TO BEGIN PROVIDING HEP-C...
INDIAN HEALTH MINISTRY URGED TO BEGIN PROVIDING HEP-C TREATMENT NOW OPPOSE PATENT ON NEW HEPATITIS C DRUG AND DEMAND AFFORDABLE ACCESS New Delhi, 21 March 2014 – With oral drugs promising to simplify...
View ArticleNatco seeks to block Gilead’s hepatitis C drug patent in India: source
Source: Reuters 11 April 2014 (Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in...
View ArticleLow Expectations For Hanoi Round Cast Doubt On November TPP Result
Source: World Trade Online 3 Sep 2014 At an informal round of talks taking place Sept. 1-10 in Hanoi, Trans-Pacific Partnership (TPP) negotiators are poised to confront some of the most contentious...
View ArticleStatement of Brazilian CSO (GTPI) on Gilead VL on sofosbuvir
Source: De Olho 22 Sep 2014 Brazil is excluded from license authorizing production of generic medicine for hepatitis C The pharmaceutical company Gilead Sciences announced last Monday (September, 15th)...
View ArticleCOMMUNITY GROUPS INTENSIFY EFFORTS TO BREAK MONOPOLY ON LIFE SAVING HEP C...
22 Sep 2014 Asian and Indian groups join hands to oppose patent application on sofosbuvir Gilead’s licensing practices leave millions in developing countries without affordable generic access Delhi and...
View ArticleCivil society opposes patent on sofosbuvir
Source: Lawyers Collective 10 September, 2014- In a move towards furthering access to affordable medicines, Lawyers Collective through Sankalp Rehabilitation Trust, the Hepatitis Coalition of Nagaland...
View ArticleIssues of concern around Commerce and Industry Minister’s Statement on IP Policy
Statement of Organisations and Individuals Tuesday, 23 September 2014 We, the undersigned organisations and individuals, understand that ahead of Prime Minister Narendra Modi’s scheduled visit to the...
View ArticleCipla asks government to revoke five patents held by Novartis
Source: Economic Times 30 Oct 2014 Cipla, India’s fifth largest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug Onbrez. NEW DELHI: Cipla,...
View ArticleThe dirty motivation behind Gilead’s hepatitis C agreement
Source: Aljazeera November 21,2014 It’s not about increasing medicine access but about ensuring market control. Up to 150 million people worldwide suffer from chronic hepatitis C, which attacks the...
View ArticleDoesn’t India Already Have an IPR Policy?
Source: Economic & Political Weekly 8 Dec 2014 The National Democratic Alliance government has constituted the IPR Think Tank which, among other things, is to draft the National Intellectual...
View ArticlePetition-Equitable Access to HCV Drugs
Source: Petition Buzz 30 Jan 2015 To: John Martin Chief Executive Officer and Chairman, Board of Directors Gilead Sciences January 28, 2015 Dear Mr. John Martin, We, the undersigned, are organizations...
View ArticlePress Release: Reaction from DNP+ on Gilead’s petition against Sofosbuvir...
New Delhi, 30 January 2015—In response to the rejection of its key patent application earlier this month for the drug sofosbuvir, used to treat hepatitis C (HCV), US pharmaceutical company Gilead...
View ArticleGilead Sciences, Inc.’s (GILD) Sovaldi Faces Patent Opposition In India
Source: BidnessEtc 3 Feb 2015 Gilead is looking at another pre-grant opposition to its patent application for Sovaldi in India, on the grounds of the drug being ineffective Gilead Sciences, Inc.’s...
View ArticleDelhi High Court sends decision of patent refusal for Gilead drug sofosbuvir...
Responses by the Delhi Network of Positive People (DNP+), and the Initiative for Medicines Access and Knowledge (I-MAK) as published on 2nd Feb 2015 The Delhi High Court decided on 30 January 2015 to...
View ArticleMaths of Gilead’s hepatitis C drug
Source: Down To Earth 3 Feb 2015 Why US firm’s super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price The indian Patent Office’s rejection of one of Gilead...
View ArticleGilead faces challenge to European patent on pricey hep C drug
Source: Reuters 12 Feb 2015 Global health charity Medecins du Monde (MdM) launched a legal challenge on Tuesday to a European patent held by U.S. drugmaker Gilead Sciences Inc which it accused of...
View ArticleWanted! American asks for ‘Made in India’ hepatitis drug for just 1% of its cost
Source : Business Insider India, June 3, 2015 An Express Scripts Holding Co. executive wanted to secure inexpensive versions of Gilead Sciences Inc.’s hepatitis C drug Sovaldi for patients in the U.S....
View ArticleChina rejects Gilead hepatitis C drug patent -advocacy group
Source: Reuters 19 June 2015 China has rejected Gilead Sciences Inc’s application for a new patent related to its costly hepatitis C drug Sovaldi, removing a potential barrier to generic versions of...
View Article
More Pages to Explore .....